MEI Pharma and Kyowa Kirin report new clinical data on Zandelisib
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
he Phase 2 TIDAL data generated to date continue to highlight zandelisib's therapeutic profile and the potential to benefit patients
The transfer of the distribution rights will strengthen Sandoz's immunology and biosimilar portfolio
HealthCare Royalty Partners funding supports the ongoing launch of IBSRELA in the United States
Subscribe To Our Newsletter & Stay Updated